Abstract
In the present study, we compared the real-time reverse-transcription polymerase chain reaction (RT-PCR) and total IgM-IgG antibody tests for diagnosis SARS-CoV-2 patients. SARS-CoV-2 patients were divided into four additional subgroups according to clinical examination, and Computed Tomography (CT) for SARS-CoV-2. Groups were included 60 mild cases, 111 moderate cases, 53 severe cases, and 105 normal cases. In a mild group, 52.5% of 60 cases were found to be male, 45.9% female, and the average age was found as 38.4 ±2.011. The positive ratio was found as 80.3% in the RT-PCR test, while 39.3% in total IgM/IgG. In a moderate group, 49.1% of 111 cases were found to be male, 50% female, and the average age was 45.05 ±1.519. The positive ratio was found as 85.7% in the RT-PCR test while 54.5% in total IgM/IgG. In a severe group, 53.7%of 53 cases were found to be male, 44.4% female, and the average age was 55.5±2.122. The positive ratio was found as 75.9% both in RT-PCR and total IgM/IgG tests. In a normal group with no involvement according to Computed Tomography (CT), 49.1%of 105 cases were found to be male, 50% female, and the average age was found as 34.8±1.391. The positive ratio was found as 95.3% in the RT-PCR test while 5.7% in total IgM/IgG. Chronic diseases were detected more in severe cases, suggesting that persons who have chronic diseases or decreased immunity, such as diabetes mellitus, cardiovascular diseases, hypertension, and lung disease, are at a higher risk for developing severe COVID-19 if they are infected with SARS-CoV-2. According to our results, we can suggest a higher detection sensibility in RT-PCR than in total IgM/IgG antibody test for mild, moderate and normal group, while the detection sensibility of IgM/IgG antibody increases in a severe group with bilateral diffuse involvement according to CT.
There is no Figure or data content available for this article
References
2. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. Lancet Respir Med. Feb 24 2020. doi:10.1016/s2213-2600(20)30079-5.
3. Chu DKW, Pan Y, Cheng SMS et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem. April 2020. doi:10.1093/clinchem/hvaa029.
4. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. Jan1 2020;25(3):2000045. doi:10.2807/1560-7917.ES.2020.25.3.2000045.
5. Vidal-Anzardo M, Solis G, Solari L, et al. Evaluation of a rapid serological test for detection of IgM and IgG antibodies against sars-cov-2 under field conditions Revista Peruana de Medicina Experimental y Salud Pública. 2020;37(2). doi:10.17843/rpmesp.2020.372.5534.
6. Wang H, Li X, Li T, et al. 2020. The genetic sequence, origin, and diagnosis of SARS-CoV-2. European Journal of Clinical Microbiology & Infectious Diseases, 1. Apr 2020. doi:10.1007/s10096-020-03899-4
7. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 Mar 28. pii: ciaa344. doi: 10.1093/cid/ciaa 344. [Epub ahead of print].
8. To KKW, Tsang OT, Leung WS et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–74. doi:10.1016/S1473-3099(20)30196-1.
9. Li Z, Yi Y, Luo X, et al. Development and clinical application of A rapid IgM-IgG combined antibody test for SARS-CoV-2 Infection Diagnosis. J Med Virol. 2020. doi:10.1002/jmv.25727.
10. Chen Z, Zhang Z., Zhai X, et al. Rapid and Sensitive Detection of anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay. Analytical chemistry. 2020; 92(10):7226-7231. doi:10.1021/acs.analchem.0c00784.
11. Liu R, Han H, Liu F, et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. ClinicaChimica Acta. 2020;505:172-175. doi:10.1016/j.cca.2020.03.009.
12. YoldaÅŸ O. COVID - 19 disease diagnosis: comparison of tests. 1st International Congress of Multidisciplinary Studies in Health Sciences / 3-5 June 2020; Page 26-30. ISBN: 978-625-7897-34-1.
13. European Centre for disease Prevention and Control. An overview of the rapid test situation for COVID-19 diagnosis in the EU/EEA. Stockholm: European Centre for disease Prevention and Control, 2020. https://www.ecdc. europa. eu/ sites/ default/ files/documents/ Overview- rapid- test- situation- for- COVID- 19- diagnosis-EU- EEA.pdf.
14. Kumar VS. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics. 2020;10(202), 1-7. doi:10.3390/diagnostics10040202.
15. Osman, O., Bolatli, G., & Tas, F. Investigation of revers-transcriptase polymerase chain reaction values of patients with COVID-19 findings in lung computed tomography results. Jurnal Teknologi Laboratorium. 2020; 9(1):41-48. doi:10.29238/teknolabjournal.v9i1.220.
16. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. Lancet Respir Med. Feb 24 2020.doi:10.1016/s2213-2600(20)30079-5.
17. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. Feb 28 2020. doi:10.1056/NEJMoa2002032.
18. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. Feb 19 2020. doi:10.1111/all.14238.
19. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. Mar 28 2020;395(10229):1054-1062. doi:10.1016/s0140-6736(20)30566-3.
20. Yen N, Lee E, Yang J, et al. Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review. Radiology: Cardiothoracic Imaging. 2020;2(1):11-15. doi:10.1148/ryct.2020200034.
How to Cite This
Article Metrics
Download Statistics
Downloads
Other Statistics
Copyright and Permissions
Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.